Pharmacokinetics of Agelastatin A in the central nervous system

Zhimin Li, Takuma Kamon, David A. Personett, Thomas Caulfield, John A. Copland, Takehiko Yoshimitsu, Han W. Tun

Research output: Contribution to journal › Article

11 Citations (Scopus)

Abstract

Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalMedChemComm
Volume3
Issue number2
DOIs
Publication statusPublished - Feb 2012
Externally publishedYes

Fingerprint

Pharmacokinetics
Neurology
Osteopontin
Central Nervous System
Brain Neoplasms
Tumors
Brain
agelastatin A

ASJC Scopus subject areas

  • Biochemistry
  • Pharmaceutical Science

Cite this

Li, Z., Kamon, T., Personett, D. A., Caulfield, T., Copland, J. A., Yoshimitsu, T., & Tun, H. W. (2012). Pharmacokinetics of Agelastatin A in the central nervous system. MedChemComm, 3(2), 233-237. https://doi.org/10.1039/c1md00240f

Pharmacokinetics of Agelastatin A in the central nervous system. / Li, Zhimin; Kamon, Takuma; Personett, David A.; Caulfield, Thomas; Copland, John A.; Yoshimitsu, Takehiko; Tun, Han W.

In: MedChemComm, Vol. 3, No. 2, 02.2012, p. 233-237.

Research output: Contribution to journal › Article

Li, Z, Kamon, T, Personett, DA, Caulfield, T, Copland, JA, Yoshimitsu, T & Tun, HW 2012, 'Pharmacokinetics of Agelastatin A in the central nervous system', MedChemComm, vol. 3, no. 2, pp. 233-237. https://doi.org/10.1039/c1md00240f
Li Z, Kamon T, Personett DA, Caulfield T, Copland JA, Yoshimitsu T et al. Pharmacokinetics of Agelastatin A in the central nervous system. MedChemComm. 2012 Feb;3(2):233-237. https://doi.org/10.1039/c1md00240f
Li, Zhimin ; Kamon, Takuma ; Personett, David A. ; Caulfield, Thomas ; Copland, John A. ; Yoshimitsu, Takehiko ; Tun, Han W. / Pharmacokinetics of Agelastatin A in the central nervous system. In: MedChemComm. 2012 ; Vol. 3, No. 2. pp. 233-237.
@article{af9f38ca70dc438982938076ce3739a0,
title = "Pharmacokinetics of Agelastatin A in the central nervous system",
abstract = "Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10{\%}. AA should be further tested for activity against brain tumors.",
author = "Zhimin Li and Takuma Kamon and Personett, {David A.} and Thomas Caulfield and Copland, {John A.} and Takehiko Yoshimitsu and Tun, {Han W.}",
year = "2012",
month = "2",
doi = "10.1039/c1md00240f",
language = "English",
volume = "3",
pages = "233--237",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of Agelastatin A in the central nervous system

AU - Li, Zhimin

AU - Kamon, Takuma

AU - Personett, David A.

AU - Caulfield, Thomas

AU - Copland, John A.

AU - Yoshimitsu, Takehiko

AU - Tun, Han W.

PY - 2012/2

Y1 - 2012/2

N2 - Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

AB - Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=84863149318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863149318&partnerID=8YFLogxK

U2 - 10.1039/c1md00240f

DO - 10.1039/c1md00240f

M3 - Article

AN - SCOPUS:84863149318

VL - 3

SP - 233

EP - 237

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 2

ER -

Access to Document